INS and metabolic disease: As it is important to find therapeutic solutions in the early stages of the pathogenesis of these complex diseases before advanced symptoms appear, we exposed WT and Tff3-deficient mice to 9 weeks of HFD treatment and observed the effects on various features of metabolic disorders, including insulin and glucose metabolism, the accumulation of lipids in the liver, and underlying molecular alterations.